Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Neurology"
DOI: 10.3389/fneur.2022.919778
Abstract: Background Pimavanserin, a selective 5-HT2A inverse agonist/antagonist, is the only treatment approved by the US Food and Drug Administration for hallucinations and delusions associated with Parkinson's disease (PD) psychosis. Aim We aimed to evaluate motor-… read more here.
Keywords: cognition related; placebo; motor cognition; pimavanserin ... See more keywords